GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Cyclically Adjusted Book per Share

Vertex Pharmaceuticals (WBO:VRTX) Cyclically Adjusted Book per Share : €23.19 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share for the three months ended in Dec. 2023 was €62.559. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €23.19 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 32.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 37.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 36.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vertex Pharmaceuticals was 38.60% per year. The lowest was -7.70% per year. And the median was 5.45% per year.

As of today (2024-04-28), Vertex Pharmaceuticals's current stock price is €372.90. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €23.19. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 16.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 13.87. And the median was 25.13.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.48 7.93 12.56 17.93 23.19

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.93 19.01 20.45 22.93 23.19

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Vertex Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=62.559/129.4194*129.4194
=62.559

Current CPI (Dec. 2023) = 129.4194.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.768 99.695 4.891
201406 3.635 100.560 4.678
201409 3.734 100.428 4.812
201412 3.606 99.070 4.711
201503 3.704 99.621 4.812
201506 3.264 100.684 4.196
201509 3.345 100.392 4.312
201512 3.503 99.792 4.543
201603 3.476 100.470 4.478
201606 3.526 101.688 4.488
201609 3.670 101.861 4.663
201612 4.416 101.863 5.611
201703 5.635 102.862 7.090
201706 5.931 103.349 7.427
201709 5.947 104.136 7.391
201712 6.769 104.011 8.423
201803 7.640 105.290 9.391
201806 9.021 106.317 10.981
201809 9.743 106.507 11.839
201812 15.278 105.998 18.654
201903 16.306 107.251 19.676
201906 17.481 108.070 20.934
201909 18.542 108.329 22.152
201912 21.146 108.420 25.242
202003 22.571 108.902 26.824
202006 25.669 108.767 30.543
202009 26.541 109.815 31.279
202012 27.475 109.897 32.356
202103 29.144 111.754 33.751
202106 29.458 114.631 33.258
202109 31.619 115.734 35.358
202112 35.125 117.630 38.646
202203 38.750 121.301 41.343
202206 44.094 125.017 45.647
202209 51.276 125.227 52.993
202212 51.101 125.222 52.814
202303 52.347 127.348 53.199
202306 55.389 128.729 55.686
202309 60.011 129.860 59.808
202312 62.559 129.419 62.559

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Vertex Pharmaceuticals  (WBO:VRTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=372.90/23.19
=16.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 13.87. And the median was 25.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (WBO:VRTX) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.